|
|
Title: Modified HIV-1gag p17
peptide and immunogenic composition
United States Patent: 7,009,037
Issued: March 7, 2006
Inventors: Sorensen; Birger (Skien, NO)
Assignee: Bionor Immuno AS (Gulset, NO)
Appl. No.: 129331
Filed: September 3, 2001
PCT Filed: September 3, 2001
PCT NO: PCT/NO01/00362
371 Date: June 11, 2002
102(e) Date: June 11, 2002
PCT PUB.NO.: WO02/20554
PCT PUB. Date: March 14, 2002
|
|
|
Training Courses --Pharm/Biotech/etc.
|
Abstract
The present invention comprises novel and
modified peptides capable of inducing a HIV-1 specific immune response
without antagonizing the cytotoxic T-cell activity in order to achieve an
effective prophylactic and therapeutic vaccine against HIV. The peptides
are based on conserved regions of HIV gag p17 and p24 proteins. Antigens
in free- or carrier-bound form comprising at least one of the said
peptides, vaccine compositions containing at least one of the antigens,
immunoassay kits and a method of detecting antibodies induced by HIV or
HIV specific peptides using such antigens, are described.
DESCRIPTION OF THE
INVENTION
The peptides according to the invention
are originating from the four different conserved areas of the HIV-1 gag
protein p17 and p24 which are described above, having the properties of
maintaining the uniqueness of the HIV-1-epitope. Further the new peptides
according to the invention possess no recognized cytotoxic T lymphocyte (CTL)
antagonistic effect and shall have at least one potential CTL epitope.
The peptides, according to the invention, which have met the above
criteria are selected from the following groups;
| Xaa1 Xaa2
Xaa3 Xaa4 Xaa5 Xaa6
Xaa7 |
(SEQ ID NO: 1) |
|
| |
| Gln Leu Gln Xaa11
Xaa12 Xaa13 Xaa14 |
| |
| Xaa15 Xaa16
Xaa17 Xaa18 Xaa19 Xaa20
Xaa21 |
wherein the amino acids of the chain
could have the following meanings;
Xaa in position 1 of the peptide
derivate is His, Lys or Arg,
Xaa in position 2 is Ile, Leu, Val or
Met,
Xaa in position 3 is Ile or Val,
Xaa in position 4 is Trp or Tyr,
Xaa in position 5 is Ala or Leu,
Xaa in position 6 is Ser, Thr, Arg or
Asn,
Xaa in position 7 is Arg or Ser,
Xaa in position 11 is Arg, Lys, Gly or
Asn,
Xaa in position 12 is Phe, Ser or Tyr
Xaa in position 13 is Ala, Thr or Ser
Xaa in position 14 is Val, Leu, Ile or
Cys,
Xaa in position 15 is Asn, Asp or Ser,
Xaa in position 16 is Pro, Arg or Ser,
Xaa in position 17 is Gly, Ser, Ala, Asp
or Asn
Xaa in position 18 is Leu or Phe,
Xaa in position 19 is Leu or Met,
Xaa in position 20 is Glu, Gly, Asp or
Ile,
Xaa in position 21 is Thr, Ser or Ala
the peptide comprises at least six consecutive amino acids of the sequence
of SEQ ID NO: 1,
| Xaa1 Xaa2
Xaa3 Xaa4 Xaa5 Xaa6
Xaa7 |
(SEQ ID NO: 4) |
|
| |
| Gly Xaa9 Leu Val
—Z—Tyr Xaa13 Xaa14 |
| |
| Xaa15 Xaa16
Xaa17 Xaa18 Xaa19 Xaa20 |
| |
| Xaa21 Ala Xaa23
Xaa24 Xaa25 Xaa26 |
wherein the amino acids of the chain have the following meaning;
Xaa in position 1 is Pro, Tyr or Phe
Xaa in position 2 is Ile, Val or Leu,
Xaa in position 3 is Ile, Ala, Val, Met
or Leu
Xaa in position 4 is Gln, Ser, Thr or
Val
Xaa in position 5 is Asn, Asp or Thr
Xaa in position 6 is Ile, Ala, Leu or
Met
Xaa in position 7 is Gln, Glu Lys or Gly
Xaa in position 9 is Gin or Ile
Xaa in position 13 is omitted
Xaa in position 14 is Ala, Ser, Asn, Val
or Pro
Xaa in position 15 is Ile, Leu, Met or
Val,
Xaa in position 16 is Ser or Thr
Xaa in position 17 is Pro or Ala,
Xaa in position 18 is Arg or Lys,
Xaa in position 19 is Thr or Ser
Xaa in position 20 is Leu or Ser
Xaa in position 21 is Asn, Phe or Val,
Xaa in position 23 is Trp, Tyr, Gly or
none
Xaa in position 24 is Val, Leu, Gly or
none
Xaa in position 25 is Lys, Arg, Gly or
none
Xaa in position 26 is Val, Ala, Cys, Gly
or none
wherein the sequence of SEQ ID NO: 4 comprises at least six consecutive
amino acids and —Z— is optional and have the meaning PEG, modified PEG
and/or [Gly]n, wherein n=1, 2 or 3,
| Xaa1 Ala Xaa3
Xaa4 Xaa5 Ala Xaa7 |
(SEQ ID NO: 9) |
|
| |
| Xaa8 Xaa9
Leu Leu Xaa12 Xaa13 |
| |
| Xaa14—Z—Xaa15
Xaa16 His Gln Xaa19 Ala |
| |
| Xaa21 Xaa22 |
wherein Xaa in position 1 is Tyr, Trp, Phe or Gly
Xaa in position 3 is Thr, Ala, Val, Ile
or Leu
Xaa in position 4 is Pro or Ser
Xaa in position 5 is Gin, His, Gly, Thr,
Ser or Tyr
Xaa in position 7 is Leu, Ile or Val
Xaa in position 8 is Asn or Tyr
Xaa in position 9 is Thr, Met, Leu or
Ala
Xaa in position 12 is Ser, Thr or Asn
Xaa in position 13 is Thr, Ile, Val or
Ala
Xaa in position 14 is Val or Ile
Xaa in position 15 is Gly or none
Xaa in position 16 is Gly or none
Xaa in position 19 is Ala or Gly
Xaa in position 21 is Met, Leu, Cys or
none
Xaa in position 22 is Gln, Glu, His, Gly
or none
wherein the sequence of SEQ ID NO: 9 consists of at least six consecutive
amino acids and the linker —Z— is optional and have the meaning PEG,
modified PEG and/or [Gly]n, wherein n=1, 2 or 3,
| Xaa1 Xaa2
Ala Leu Ala Gly Xaa7 |
(SEQ ID NO: 15) |
|
| |
| Xaa8 Xaa9
Leu Xaa11 Xaa12 Xaa13 |
| |
| Xaa14 Xaa15
Xaa16 Xaa17 Xaa18 Xaa19 |
| |
| Xaa20 Xaa21 |
wherein the Xaa in position 1 is Trp or Tyr
Xaa in position 2 is Ser or Ala
Xaa in position 7 is Thr, Ala or Ser
Xaa in position 8 is Ser or Thr
Xaa in position 9 is Ser or Thr
Xaa in position 11 is Leu, Pro, Val or
Gln
Xaa in position 12 is Gln, Ala or His
Xaa in position 13 is Glu or Gly
Xaa in position 14 is Gln or His
Xaa in position 15 is Ile, Leu, Val or
Met
Xaa in position 16 is Gly, Ala, Gln, Thr,
Asn, Arg, His or Ile
Xaa in position 17 is Trp or Tyr
Xaa in position 18 is Thr, Met, Leu or
Ile
Xaa in position 19 is Thr or Ser
Xaa in position 20 is Cys, Gly or none
Xaa in position 21 is Gly or none
wherein the sequence of SEQ ID NO: 15 consists of at least six consecutive
amino acids,
the terminal ends of the sequences may be free carboxyl- or amino groups,
amides, acyls, acetyls or salts thereof,
two or more of the Cys residues may form part of an interchain disulphide
binding, a —S—(CH2)p—S— or a —(CH2)p-bridge
wherein p=1-8, optionally intervened by one or more hetero atoms such as
O, N or S and/or the said peptide sequences are immobilized to a solid
support.
The new peptide sequences have the potential to serve as a good antigen
wherein the antigen comprises at least one peptide selected from the group
of sequences of SEQ ID NO: 1, SEQ ID NO: 4, SEQ ID NO: 9 or SEQ ID NO: 15.
The antigenicity may be adapted through adjusting the ratio or
concentration of different peptides or size of the peptides by for
instance dimerization or polymerization and/or immobilization to a solid
phase. The antigen comprises two or more polypeptide sequences, according
to the invention, which are either linked by a bridge for instance a
disulphide bridge between the Cys residues of the chains or bridges like C1-C8
alkylen possibly intervened by one or more heteroatoms like O, S, or N or
preferably they are unlinked. The chains may be immobilized to a solid
phase in monomeric, dimeric or oligomeric forms. Further amino acids may
be added to the ends in order to achieve an <<arm>> to facilitate
immobilization.
PEG is polyethylene glycol (HO(CH2CH2O)mH
and can be part of the linker —Z—, optionally PEG is modified by a
dicarboxylic acid (HO(CH2CH2O)mCO(CH2)oCOOH)
or a terminal carboxylic group (HO(CH2CH2O)m-1CH2COOH)
where m=1-10 and o=2-6, prior to linking.
The linker —Z— can either consist of PEG, modified PEG, or a combination
thereof and/or one or more Gly residues combined. Alternatively the linker
—Z— can consist of a Gly-bridge [Gly]n where n=1, 2 or 3.
All amino acids in the peptides of the invention can be in both D- or
L-form, although the naturally occurring L-form is preferred.
The C- and N-terminal ends of the peptide sequences could deviate from the
natural sequences by modification of the terminal NH2-group
and/or COOH-group, they may for instance be acylated, acetylated, amidated
or modified to provide a binding site for a carrier or another molecule.
The peptides according to the invention are consisting of at least 6 amino
acids, preferably between 10 and 30 amino acids. They are covering all
natural variation of amino acids in the identified positions.
The polypeptide antigen according to the invention is either in a free or
in a carrier-bound form. The carrier or solid phase to which the peptide
is optionally bound can be selected from a vide variety of known carriers.
It should be selected with regard to the intended use of the immobilized
polypeptide as a diagnostic antigen or as an immunizing component in a
vaccine.
Examples of carriers that can be used for e.g. diagnostic purposes are
magnetic beads or latex of co-polymers such as styrene-divinyl benzene,
hydroxylated styrene-divinyl benzene, polystyrene, carboxylated
polystyrene, beads of carbon black, non-activated or polystyrene or
polyvinyl chloride activated glass, epoxy-activated porous magnetic glass,
gelatine or polysaccharide particles or other protein particles, red blood
cells, mono or polyclonal antibodies or fab fragments of such antibodies.
According to a further embodiment of the present invention, the antigens
may form part of a vaccine possibly combined with carriers, adjuvants or
combined with other immunostimulating elements such as canarypox virus
carrying the env gene. Examples of carriers and/or adjuvants for vaccine
purposes are other proteins such as human or bovine serum albumin and
keyhole limpet haemocyanin and fatty acids. Immunostimulatory materials
may be divided into three groups; adjuvants, carriers for antigens and
vehicles. Examples of adjuvants include aluminum hydroxyd, aluminum salts,
saponin, muramyl di and tripeptides, monophosphoryl lipid A, palmitic
acid, B.pertussis and various cytokines including the Th1 cytokine
IL-12 and IL-1. A number of protein toxins can be used to carry passenger
proteins across cellular membranes into the cytosol, which are useful in
developing CTL vaccines. Carriers include bacterial toxoids such as
inactivated tetanus and cholera toxins, genetically detoxified bacterial
toxins such as heat labile enterotoxin from E. coli, fatty acids,
live vectors such as polio chimeras and hybrid proteins that form
particulates for example yeast retrotransposon hybrid TY particles and
HBcAg particles. Vehicles which are frequently occurring components in
modern vaccines are consisting of mineral oil emulsion, Freunds complete
and incomplete adjuvant, vegetable oil emulsions, nonionic block
co-polymer surfactants, squalene or squalane, lipopeptides, liposomes and
biodegradable microspheres. Two recent adjuvants which possess significant
potential for the development of new vaccines include an oil-in- water
microemulsion (MF59) and polymeric microparticles. Any substance that can
enhance the immunogenicity of the antigen may be used and several further
alternatives of carriers or adjuvants are given in the US or European
Pharmacopoeia.
A suitable formulation of the antigen for immunostimulatory uses may also
comprise interferons such as INF-γ, antiviral chemokines or haematopoietic
growth factors such as granulocyte macrophage growth (colony stimulating)
factor.
Another approach in order to enhance the stimulation and absorption in for
instance the intestine is to administer the peptides of the invention,
with small peptides such as di, tri or tetrapeptides. These peptides can
be administered in addition to or in combination with the peptides of the
invention. Preferably the peptides are administered together with the
tripeptide YGG, consisting of amino acids in the D- or L-forms, preferably
in the D-form.
Recent approaches to non-parenteral delivery of vaccines, for instance via
mucosa include; gene fusion technology to create non-toxic derivatives of
mucosal adjuvants, genetically inactivated antigens with a deletion in an
essential gene, co-expression of an antigen and a specific cytokine that
is important in the modulation and control of a mucosal immune response,
and genetic material itself that would allow DNA or RNA uptake and its
endogenous expression in the host cells.
One approach for developing durable responses where cell-mediated immunity
is required, is to vaccinate with plasmid DNA encoding one or more
specific antigen(s).
In order to protect against HIV infection, vaccines should induce both
mucosal and systemic immune responses and could be administered by any
convenient route, parenterally or non-parenterally, such as subcutanously,
intracutanously, intravenously, intramuscularly, perorally, mucosally or
intranasally for example.
In a preferred embodiment of the vaccine according to the present
invention it comprises antigens containing at least one of the peptides
selected from the groups of SEQ ID NO: 1, 4, 9 and 15, more preferred
different peptides occur in equal amounts.
In a further preferred embodiment the vaccine composition contains the
antigens;
| R L I Y A T R Q L Q R F A V
N P G L L I T-NH2 |
(SEQ ID NO: 3) |
|
| |
| F I L Q N I E G Q L V G G G Y A I
S P R T L V A G G G G |
(SEQ ID NO: 6) |
| |
| Y A I P Q A L N T L L N T V
G G H Q A A-NH2 |
(SEQ ID NO: 11) |
| and |
| |
| W S A L A G T T S L L Q G Q
L G W I T-NH2 |
(SEQ ID NO: 14) |
The sequences contribute with
CTL-epitopes and can activate the cellular immune system. The amino acid
changes implemented within the frame of the CTL-epitopes are designed to
achieve enhanced binding. Other amino acid changes have been conducted in
order to facilitate the synthesis of the peptide and/or to increase the
solubility of the peptide.
A method for detecting antibodies, induced by HIV-1 or HIV-1 specific
peptides or proteins, in a sample of body fluid using the present antigens
is a further embodiment of the invention. Also immunoassay kit designed
for this detection and antibodies capable of selectively reacting with the
said antigens are encompassed by the present invention.
Description of the Preparation of the Peptides
The peptides of the invention can be produced by any known method of
producing a linear amino acid sequence, such as recombinant DNA
techniques. A nucleic acid sequence which encodes a peptide of the
invention or a multimer of the said peptides, is introduced into an
expression vector. Suitable expression vectors are for instance plasmids,
cosmids, viruses and YAC (yeast artificial chromosome) which comprise
necessary control regions for replication and expression. The expression
vector may be stimulated to expression in a host cell. Suitable host cells
are for example bacteria, yeast cells and mammalian cells. Such techniques
are well known in the art and described for instance by Sambrook et al.,
Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, 1989. Other well-known techniques are
degradation or synthesis by coupling of one amino acid residue to the next
one in liquid phase or preferably on a solid phase (resin) for instance by
the so-called Merrifield synthesis. See for instance Barany and Merrifield
in the Peptides, Analysis, Synthesis, Biology, Vol. 2, E. Gross and
Meinhofer, Ed. (Acad. Press, N.Y., 1980), Kneib-Coronier and Mullen Int.
J. Peptide Protein Res. 30, p. 705-739 (1987) and Fields and Noble
Int.J.Peptide Protein Res., 35, p. 161-214 (1990).
In case a linked or cyclic peptide is desired, the amino acid sequence is
subjected to a chemical oxidation step in order to cyclize or link the two
cysteine residues between two peptide sequences, when the appropriate
linear amino acid sequences are synthesized, see Akaji et al., Tetrahedron
Letter, 33, 8, p. 1073-1076, 1992.
General Description of Synthesis
All peptide derivatives prepared in the Examples given below were
synthesized on a Milligen 9050 Peptide Synthesizer using a standard
program. The resin used was Tenta Gel P RAM with a theoretical loading of
0.20 meq/g (RAPP POLYMERE GmbH, Tübingen). The final product of the
synthesis was dried in vacuo overnight. The peptide was then cleaved from
the resin by treatment with 90% trifluoroacetic acid in the presence of
ethane dithiol (5%) and water (5%) as scavengers (1.5 hours at RT). Then
the resin was filtered and washed on filter with additional
trifluoroacetic acid (100%) (2×20 ml). The combined filtrates were
evaporated in vacuo (water bath at RT) and the residue was triturated with
ethyl ether (200 ml) and the precipitated product filtered off. The solid
was promptly dissolved on filter with glacial acetic acid (100 ml) and
added to 1.5 l of 20% acetic acid in methanol and treated with 0.1 M
solution of iodine in methanol until a faint brown colour remained. Then
Dowex 1×8 ion exchange in acetate form (15 g) (Bio-Rad, Richmond, Calif.)
was added and the mixture filtered. The filtrate was evaporated and the
residue freeze-dried from acetic acid. The product was then purified by
reversed phase liquid chromatography on a column filled with Kromasil®
100-5 C8 (EKA Nobel, Surte, Sweden) in a suitable system containing
acetonitrile in 0.1% trifluoroacetic acid water solution. The samples
collected from the column were analyzed by analytical high performance
liquid chromatography (HPLC) (Beckman System Gold, USA) equipped with a
Kromasil® 100-5 C8 Column (EKA Nobel, Surte, Sweden). Fractions containing
pure substance were pooled, the solvent was evaporated and the product
freeze-dried from acetic acid. The final HPLC analysis was performed on
final product, and the structure of the peptide was confirmed by amino
acid analysis and mass spectrometry (LDI-MS).
All amino acids used during the synthesis were L-amino acids and they were
protected with a fluorenylmethoxy-carbonyl group at the α-amino function.
The side chains were protected as follows:
Cys (Trt), Gln(Trt), Glu(OtBu), Thr(tBu).
The abbreviations, within the brackets are:
Trt=triphenylmethyl
t-Bu=tert. Butyl
OtBu=tert. Butylester
The amino acid derivatives was supplied by Bachem AG, Switzerland.
Claim 1 of 7 Claims
1. An isolated HIV-1 gag p17
peptide comprising the amino acid sequence of SEQ ID NO: 3, wherein the
terminal ends of the sequence may be free carboxyl- or amino groups, amides,
acyls, acetyls or salts thereof and/or the sequence is immobilized to a
solid support.
____________________________________________
If you want to learn more
about this patent, please go directly to the U.S.
Patent and Trademark Office Web site to access the full
patent.
|